# TriWise Capital

> TriWise Capital is a VC fund backing Health Care and Biotechnology. See 28 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shenzhen, China
- Total investments: 28
- Last investment: Mar 2026
- Lead investor: 36%
- Last updated: Aug 2026
- Website: http://www.triwise.cn/

TriWise Capital is an investment firm that focuses on venture capital and M&A business.

## Contacts

5 contacts available for TriWise Capital. Shizune tracks 1 team members at TriWise Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/triwise-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 46% |
| Biotechnology | 12 | 43% |
| Medical | 10 | 36% |
| Pharmaceutical | 9 | 32% |
| Biopharma | 7 | 25% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 21% |
| Series B | 6 | 21% |
| Seed | 5 | 18% |
| Series C | 5 | 18% |
| Angel | 3 | 11% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 21 | 75% |
| United States | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dajie Tang | Founding Partner | 0 | https://shizune.co/investors/profile/dajie-tang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bite Micro | Better Micro Medical is a medical device company that is characterized by intervention and non-implantation, and offers doctors with comprehensive solutions in the field of peripheral vascular and structural heart disease. | $14.5M | Series B | Mar 16, 2026 |  |
| Chongqing Hanpei Biotechnology | Chongqing Hanpei Biotechnology focuses on the development of innovative and generic drugs for pets. | $1.4M | Seed | Dec 02, 2025 |  |
| Punuokang Biotechnology | Punuokang Bio is a veterinary pharmaceutical developer focusing on innovative treatments for pet metabolic diseases like heart disease, tumors, and kidney disease, which aligns with wider industry trends of advancing pet medicines for chronic conditions in companion animals. | $1.4M | Angel | Jul 29, 2025 |  |
| Novlead Biotech | Novlead Biotech contributes to a safer and healthier human well-being through our technological innovations. |  | Series C | Apr 15, 2025 |  |
| Mitouke Biopharma | Mitouke Biopharma is a manufacturer and supplier specializing in probiotics, enzymes, nutraceuticals, and feed supplements. The company produces high-quality products such as pre-probiotics, pharmaceutical enzymes, and nutraceutical supplements that are used across industries including pharmaceuticals, food, detergents, textiles, and veterinaryformulations. |  | Seed | Apr 07, 2025 |  |
| Yaoyi Life | Yaoyi Life Sciences develops animal health drugs, including vaccine adjuvants and antibacterial materials. |  | Angel | Feb 10, 2025 |  |
| Crystal Egg Bio | Crystal Egg is a biopharmaceutical company dedicated to the independent research and development of first in class innovative new drugs for major diseases such as depression, chronic kidney disease, pain and rare diseases, as well as providing customers with high-quality products and R&D services in membrane protein-related fields. enterprise.The company has built membrane protein expression and purification platforms, structural biology platforms, pharmacology platforms and nanobody screening platforms, and has rich R&D pipelines in the fields of ion channels and GPCRs. | $1.4M | Series A | Sep 13, 2024 |  |
| BiyoPharma | BiyoPharma focuses on the research and development of innovative drugs for neurological diseases, including episodic and chronic migraines, through international technology platforms and improved treatment options. |  | Seed | Apr 26, 2024 |  |
| Baikuirui | Baikuirui is an antibiotic resistance biosynthesis developer. | $1.4M | Series A | Apr 23, 2024 |  |
| Shentuo Biotechnology | Shentuo Biotechnology is a platform for gene therapy and revolutionary delivery technology that focuses on novel gene therapy medication developments. |  | Angel | Dec 29, 2023 |  |

10 of 28 investments shown.

## Co-investors
- [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 3 deals together
- [Qinzhi Capital](https://shizune.co/investors/profile/qinzhi-capital) — VC Fund, 3 deals together
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 3 deals together
- [China Highrun Capital Limited](https://shizune.co/investors/profile/china-highrun-capital-limited) — VC Fund, 2 deals together
- [CICC](https://shizune.co/investors/profile/cicc) — VC Fund, 2 deals together
- [Guangdong Technology Financial Group](https://shizune.co/investors/profile/guangdong-technology-financial-group) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does TriWise Capital invest in?

TriWise Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 28 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact TriWise Capital?

Public channels for TriWise Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at TriWise Capital?

The team at TriWise Capital includes Dajie Tang (Founding Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co